Company Description
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases.
The company’s lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.
It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gerald Proehl |
Contact Details
Address: 3525 Del Mar Heights Road, Suite 332 San Diego, California 92130 United States | |
| Phone | 858 800 2543 |
| Website | dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001853816 |
| CUSIP Number | 249845108 |
| ISIN Number | US2498453065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer and Chairman |
| David F. Hale | Co-Founder and Lead Independent Director |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President and Chief Development Officer |
| Sean Proehl | Associate General Counsel |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13D/A | Filing |
| Feb 5, 2025 | EFFECT | Notice of Effectiveness |
| Feb 5, 2025 | 424B3 | Prospectus |
| Feb 4, 2025 | D/A | Filing |